About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ADIL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Parti…
NCT07888569 · Healthy
DZD8586, Rabeprazole
AZR
Dizal Pharmaceuticals
Phase 1Recruiting
was not yet recruiting
26Nov 23, 2026Registry ↗
Oct 29, 2026A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-s…
NCT05668988 · Non-small Cell Lung Cancer
sunvozertinib, Pemetrexed+carboplatin
AZR
Dizal Pharmaceuticals
Phase 3Active, not recruiting324Jan 16, 2026Registry ↗
Oct 23, 2026Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCL…
NCT07079475 · Non-Small Cell Lung Cancer
DZD6008, Sunvozertinib
AZR
Dizal Pharmaceuticals
Phase 1/2Recruiting220Jun 2028Registry ↗
Oct 23, 2026A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC…
NCT06905197 · Non Small Cell Lung Cancer
DZD6008, Sunvozertinib
AZR
Dizal Pharmaceuticals
Phase 1Recruiting140Sep 2027Registry ↗
Oct 22, 2026Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
NCT07496229 · T-cell Lymphomas
GW5282 combined with Golidocitinib, GW5282 combined with Go…
AZR
Dizal Pharmaceuticals
Phase 1/2Recruiting220Sep 2029Registry ↗
Oct 22, 2026A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC…
NCT06295432 · Non-small Cell Lung Cancer
DZD9008+AZD4205
AZR
Dizal Pharmaceuticals
Phase 2Completed30Jun 8, 2026Registry ↗
Aug 31, 2026DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutatio…
NCT07070440 · Non Small Cell Lung Cancer
DZD6008, Pemetrexed
AZR
Dizal Pharmaceuticals
Phase 1/2Recruiting180Jun 2027Registry ↗
Aug 28, 2026Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (…
NCT06813365 · Nonsmall-cell Lung Cancer
DZD6008
AZR
Dizal Pharmaceuticals
Phase 1Recruiting300Oct 30, 2027Registry ↗
Aug 5, 2026Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588 · Diffuse Large B-Cell Lymphoma (DLBCL)
Birelentinib, Rituximab
AZR
Dizal Pharmaceuticals
Phase 2/3Not yet recruiting880Jan 2031Registry ↗
Aug 4, 2026DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
NCT06539195 · Diffuse Large B Cell Lymphoma
DZD8586, DZD8586
AZR
Dizal Pharmaceuticals
Phase 2Completed59Jun 10, 2026Registry ↗
Jul 2, 2026DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05824585 · Lymphoma, Non-Hodgkin
DZD8586
AZR
Dizal Pharmaceuticals
Phase 1Completed17Jun 30, 2025Registry ↗
Jun 22, 2026A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DZD8586, Venetoclax
AZR
Dizal Pharmaceuticals
Phase 2Recruiting66Dec 2029Registry ↗
Jun 8, 2026A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162 · Peripheral T-cell Lymphoma
Golidocitinib, Chidamide
AZR
Dizal Pharmaceuticals
Phase 3Recruiting218Nov 30, 2027Registry ↗
Jun 3, 2026A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT07139873 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DZD8586, Bendamustine
AZR
Dizal Pharmaceuticals
Phase 3Recruiting250Jan 2029Registry ↗
Jun 2, 2026DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DZD8586, DZD8586
AZR
Dizal Pharmaceuticals
Phase 2Recruiting155Sep 2027Registry ↗
May 14, 2026A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
NCT07454863 · Lymphoma, Non-Hodgkin
DZD8586
AZR
Dizal Pharmaceuticals
Phase 1Completed6Mar 27, 2026Registry ↗
Apr 1, 2026DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650 · Diffuse Large B-Cell Lymphoma
DZD8586+R-CHOP, DZD8586+R-GemOx
AZR
Dizal Pharmaceuticals
Phase 1/2Recruiting150Oct 2030Registry ↗
Feb 11, 2026A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
NCT07328217 · Advanced Solid Tumors
GW5282, GW5282
AZR
Dizal Pharmaceuticals
Phase 1/2Recruiting203Dec 2028Registry ↗
Jan 29, 2026Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung C…
NCT03974022 · Non-Small Cell Lung Cancer
Sunvozertinib
AZR
Dizal Pharmaceuticals
Phase 1/2Active, not recruiting315Jul 29, 2024Registry ↗
Jan 22, 2026A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
NCT07294365 · Immune Thrombocytopenia (ITP)
DZD8586 dose level 1, DZD8586 dose level 2
AZR
Dizal Pharmaceuticals
Phase 2Recruiting60Jul 2027Registry ↗
Dec 24, 2025AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
NCT06511895 · Peripheral T Cell Lymphoma
AZD4205
AZR
Dizal Pharmaceuticals
Phase 2Completed57Oct 17, 2025Registry ↗
Jul 4, 2025AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
NCT06511869 · Peripheral T-cell Lymphoma
AZD4205
AZR
Dizal Pharmaceuticals
Phase 2Completed48Mar 31, 2025Registry ↗
Jun 19, 2025DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR…
NCT06276283 · Non-small Cell Lung Cancer
DZD9008 plus Bevacizumab
AZR
Dizal Pharmaceuticals
Phase 2Recruiting60Dec 31, 2025Registry ↗
Apr 4, 2025Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT…
NCT04105010 · Relapsed or Refractory Peripheral T Cell Lymphoma
golidocitinib
AZR
Dizal Pharmaceuticals
Phase 1/2Completed171Oct 12, 2023Registry ↗
Apr 1, 2025DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients…
NCT04509596 · Breast Cancer Metastatic
DZD1516 mono therapy in Part A, DZD1516 in combination with…
AZR
Dizal Pharmaceuticals
Phase 1Completed23Jul 7, 2022Registry ↗
Feb 25, 2025Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell…
NCT04148742 · Non-Hodgkin's B-cell Lymphoma
DZD9008
AZR
Dizal Pharmaceuticals
Phase 1/2Withdrawn0Jul 2023Registry ↗
Feb 21, 2025A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
NCT05844956 · Lymphoma, Non-Hodgkin
DZD8586
AZR
Dizal Pharmaceuticals
Phase 1/2Completed17Feb 29, 2024Registry ↗
Dec 30, 2024Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-…
NCT05712902 · Non-Small Cell Lung Cancer
Sunvozertinib
AZR
Dizal Pharmaceuticals
Phase 2Active, not recruiting104Oct 17, 2022Registry ↗
Dec 18, 2024DZD9008 PK Study in Hepatic Impairment Subjects
NCT06084104 · Hepatic Impairment
DZD9008, DZD9008
AZR
Dizal Pharmaceuticals
Phase 1Completed17Jun 12, 2024Registry ↗
Dec 13, 2024Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for C…
NCT05926180 · Non-small Cell Lung Cancer
DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)
AZR
Dizal Pharmaceuticals
Phase 1Completed25May 16, 2024Registry ↗
Apr 17, 2024Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter…
NCT04101227 · Alcohol Use Disorder
AD04 (ondansetron), Matching placebo
AZR
Adial Pharmaceuticals
Phase 3Completed302Feb 18, 2022Registry ↗
Jun 23, 2023Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine
NCT05418582 · Healthy Subjects
DZD9008 and intraconazole, DZD9008 and carbamazepine
AZR
Dizal Pharmaceuticals
Phase 1Completed40Jun 1, 2022Registry ↗
Feb 1, 2023Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
NCT05486949 · Healthy Subjects
AZD4205 and carbamazepine, AZD4205 and itraconazole
AZR
Dizal Pharmaceuticals
Phase 1Completed32Oct 8, 2022Registry ↗
Jul 11, 2022Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
NCT04634344 · Metastatic Castration Resistant Prostate Cancer
DZD2269
AZR
Dizal Pharmaceuticals
Phase 1Terminated16May 5, 2022Registry ↗
Jul 1, 2022A Study of DZD2269 in Healthy Adult Participants
NCT04932005 · Healthy Volunteers
DZD2269, placebo
AZR
Dizal Pharmaceuticals
Phase 1Completed72Apr 1, 2022Registry ↗
Jun 2, 2022Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Me…
NCT04909242 · Healthy Volunteers
DZD9008, Placebo
AZR
Dizal Pharmaceuticals
Phase 1Completed78Feb 7, 2022Registry ↗
May 25, 2022Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
NCT05159895 · Healthy Volunteers
[14C]-DZD9008
AZR
Dizal Pharmaceuticals
Phase 1Completed8Mar 30, 2022Registry ↗
Aug 24, 2020Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male V…
NCT04225208 · Healthy Volunteers
[14C]-AZD4205, single 50 mg oral dose administrated on day 1
AZR
Dizal Pharmaceuticals
Phase 1Completed8Mar 2, 2020Registry ↗
Aug 24, 2020A Study of AZD4205 in Healthy Adult Subjects
NCT03728023 · Healthy Volunteers
AZD4205, Placebo
AZR
Dizal Pharmaceuticals
Phase 1Completed66Aug 20, 2019Registry ↗
Aug 24, 2020Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who…
NCT03450330 · Nonsmall Cell Lung Cancer
AZD4205
AZR
Dizal Pharmaceuticals
Phase 1/2Completed10Sep 3, 2019Registry ↗

40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:46 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances